Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

NCT07206758 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: SHR-2173 Injection

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd